Showing results (1051-1060 of 1,878) with videos related to
Sort By:
Pageof 188
Immunotherapy|February 25, 2021
A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositisAdi Kartolo, Tanveer Towheed, Mihaela MatesImmunotherapy|September 27, 2019
Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilarMichael Thomas, Nick Thatcher, Jerome Goldschmidt, et al.Immunotherapy|September 4, 2019
Nasal instillation of probiotic extracts inhibits experimental allergic rhinitisXian-Hai Zeng, Gui Yang, Jiang-Qi Liu, et al.Immunotherapy|October 24, 2018
Combination of PD-1 blockade and RetroNectin®-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective studyLingdi Zhao, Lu Han, Yong Zhang, et al.Immunotherapy|November 9, 2018
Factors associated with immunotherapy selection in patients with advanced melanomaRichard W Joseph, Alicia C Shillington, Cynthia Macahilig, et al.Immunotherapy|November 11, 2021
Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatmentXuqi Sun, Ziliang Yang, Yuhao Tang, et al.Immunotherapy|July 31, 2019
Pseudoprogression: an indicator for cure in combined immunotherapy?Lingdi Zhao, Yonghao Yang, Wei Li, et al.Immunotherapy|July 31, 2019
Recent advances with Treg depleting fusion protein toxins for cancer immunotherapyPankaj Kumar, Amit Kumar, Sadiya Parveen, et al.Immunotherapy|July 31, 2019
MiR-146a mimic attenuates murine allergic rhinitis by downregulating TLR4/TRAF6/NF-κB pathwayJia Wang, Zheqing Cui, Lei Liu, et al.Immunotherapy|May 13, 2014
Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?Michael P Brown, Alexander H StaudacherPageof 188